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ABSTRACT
Background: Psoriasis vulgaris is commonly
treated with topical corticosteroids and vitamin D analogues. Although potent and superpotent topical corticosteroids are very effective
at clearing psoriasis, with short-term reactive
treatment durations, symptoms usually recur
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after treatment discontinuation, necessitating
long-term disease management strategies. A
foam formulation of calcipotriol and betamethasone dipropionate (Cal/BD foam), consisting of calcipotriol 50 lg/g and betamethasone dipropionate 0.5 mg/g, is approved for the
daily treatment of psoriasis for up to 4 weeks.
Here, we describe a clinical trial protocol for
evaluating the long-term safety and efficacy of
twice-weekly Cal/BD foam as a proactive topical
maintenance therapy for plaque psoriasis for up
to 52 weeks.
Objective: The aim of this trial was to evaluate
the safety and efficacy of Cal/BD foam when
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applied twice weekly for up to 52 weeks as
proactive maintenance therapy, with the goal of
preventing or delaying disease relapse as long as
possible while minimizing adverse effects.
Methods: Once-daily Cal/BD foam treatment
responders from an initial 4-week open-label
period were randomized to receive Cal/BD foam
or foam vehicle applied to previously cleared
plaques twice weekly for up to 52 weeks. In case
of relapse, affected subjects in either group
received rescue therapy with once-daily Cal/BD
foam for 4 weeks on active areas. Thus, the trial
(NCT02899962) compared the long-term use of
Cal/BD foam in a proactive approach with a
conventional, reactive approach.
Planned Outcomes: Efficacy endpoints included the time to first relapse, the number of
relapse-free days, and the number of relapses
during the maintenance phase. Safety assessments included adverse events, incidence of
rebound, local safety and tolerability scores, and
effects on calcium metabolism and hypothalamic–pituitary–adrenal axis function.
Trial registration: ClinicalTrials.gov identifier,
NCT02899962.
Keywords: Calcipotriol/betamethasone
dipropionate (Cal/BD) foam; Double-blind;
Efficacy; Long-term treatment; Phase 3;
Proactive management; Psoriasis vulgaris;
Rebound; Safety
Key Summary Points
Why carry out this study?
Optimal management of psoriasis should
include strategies for both the initial,
rapid relief of symptoms and the longterm prevention of disease relapse;
however, long-term use of potent and
super-potent steroids as monotherapy is
associated with safety concerns
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We sought to determine if the use of
twice-weekly Cal/BD aerosol foam in a
novel, proactive treatment regimen for up
to 52 weeks could prevent or delay disease
relapse in patients with psoriasis vulgaris
while minimizing local and systemic
adverse events
The PSO-LONG trial is the first
randomized, double-blind, long-term
study of its kind to use a topical treatment
to maintain psoriasis status as ‘‘clear’’ or
‘‘almost clear’’ for up to 1 year using a
patient-friendly approach with just twiceweekly application of a single, fixedcombination product
What was learned from the study?
We hypothesized that the time to first
relapse in patients with previously cleared
skin would be prolonged in those who
received proactive therapy with twiceweekly Cal/BD foam as compared with the
outcome for patients treated with a
conventional, as-needed, reactive
approach in which active drug was only
administered after relapse occurred
Superior efficacy of the proactive
management with Cal/BD foam was
anticipated to be evidenced by a greater
number of relapse-free days and fewer
relapses compared with controls; a
favorable long-term safety profile was also
projected
The outcomes of this novel study will
provide valuable insights into the ability
of Cal/BD foam to provide a solution for
the long-term management of psoriasis in
patients with all disease severities and
thereby advance the treatment options
that can maintain clear skin for patients
with this chronic, recurring disease
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DIGITAL FEATURES
This article is published with digital features to
facilitate understanding of the article. You can
access the digital features on the article’s associated Figshare page. To view digital features for
this article go to https://doi.org/10.6084/m9.
figshare.12834647.

INTRODUCTION
Background on Psoriasis
Psoriasis is a chronic, immune-mediated, multisystem disease that primarily affects the skin
and joints [1, 2]. The most common form of this
condition, plaque psoriasis, manifests as sharply
demarcated, scaling, and erythematous lesions
that may vary in shape and size [1, 3]. Plaques
are predominantly located on the extensor sides
of the knees and elbows, but they may also be
anywhere on the body [1, 3].
Epidemiology
Estimates suggest that psoriasis affects as many
as 7.5 million people in the USA and more than
125 million people worldwide [4–6]. Within
this population, approximately 80% of patients
have mild-to-moderate and/or localized disease
that can be successfully treated with topical
medications; approximately 20% of patients
have moderate-to-severe disease that often
requires treatment with systemic medications
[7–9]. Despite the numerous treatment options
that are currently available for psoriasis, more
than half of patients report being dissatisfied
with their treatment, and a significant number
of patients continue to have residual plaques
that require long-term maintenance therapy [7].
Current Treatment Strategies
Because there is no cure for psoriasis, treatment
strategies aim to clear active disease sites and
prolong symptom-free periods [7]. Currently
available topical agents for mild-to-moderate
psoriasis include corticosteroids, vitamin D
analogues, tazarotene, anthralin, calcineurin
inhibitors, and tar [8, 9]. Potent biologic
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therapies have been developed for use in
patients with moderate-to-severe psoriasis [10];
nevertheless, topical therapies continue to be
an effective means to complement systemic
therapies in this hard-to-treat population [8, 9].
In fact, almost all patients utilizing systemic
therapy continue the use of topical therapies,
which highlights the importance of topicals for
effective management of chronic psoriasis.
Topical corticosteroids are the mainstay of
therapy for the management of mild-to-moderate psoriasis [8, 9]. These agents, available in
many strengths, formulations, and combinations, exert their therapeutic effects via antiinflammatory, antiproliferative, and immunosuppressive pathways that contribute to their
use for psoriasis and other immune-mediated
disorders [8, 9, 11]. Their therapeutic advantages notwithstanding, topical corticosteroids
carry the risk of local and systemic adverse
events (AEs), such as suppression of the
hypothalamic–pituitary–adrenal (HPA) axis,
which may complicate long-term use [8, 9, 11].
Furthermore, some patients have a phobia
about using topical corticosteroids, and their
anxiety concerning possible overapplication of
a topical steroid may lead to reduced compliance and thus poor treatment outcomes [12].
Various studies have demonstrated the therapeutic benefits of alternating between different
topical agents on different days, such as adding
a weekday nonsteroidal agent to a weekend
pulse therapy regimen [13–17]. A common
sequential regimen with topical therapy consists of applying halobetasol propionate (HP), a
potent topical corticosteroid, once daily in the
morning, and using calcipotriol ointment, a
vitamin D analogue, once daily in the evening
for approximately 1 month [18]. Subsequently,
calcipotriol is administered twice daily on
weekdays, and HP is administered twice daily
on weekends, until symptoms fully resolve, at
which point treatment will be tapered [18].
Although evidence supports the use of
sequential therapy in maintaining clinical
improvements [19–21], patient adherence can
be problematic. Adherence to topical therapy
may improve with the use of a single, fixedcombination treatment, rather than expecting
the patient to apply two or more distinct topical
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agents in the right order [9, 22–24]. In addition,
the ability to effectively maintain relapse-free
periods for psoriasis may not be possible using
an as-needed, reactive treatment approach,
whereas implementing a proactive strategy may
reduce relapse rates [25, 26]. The concept of
proactive therapy, defined as the administration
of a long-term, low-dose, intermittent treatment, has been successfully used for atopic
dermatitis [27] and scalp psoriasis [26, 28], but it
has not yet been rigorously examined for psoriasis affecting the body. We conducted this
trial on the use of a fixed-combination treatment for long-term proactive maintenance
therapy for psoriasis, with the objective of
obtaining rigorous scientific data to support this
therapeutic approach and its potential use in
clinical practice as a part of chronic psoriasis
management.
Long-Term Clinical Studies of Topical Agents
for Treatment of Psoriasis
Although topical steroids play a key role in the
treatment of psoriasis, it is generally recommended not to exceed 4 weeks of daily topical
steroid monotherapy because of the potential
risk of AEs. This limitation on treatment duration of topical steroids can be problematic for
the long-term management of psoriasis, and it
has led to the common use of a reactive, asneeded treatment approach that fails to address
relapse prevention.
The need for long-term treatment strategies is
acknowledged, and such strategies might combine treatment with nonsteroidal agents, such as
vitamin D analogues, to minimize steroid exposure. However, there is no standard as to which
topical combinations are best, resulting in highly
variable treatment plans. Proactive strategies are
an additional long-term treatment option
[25, 26, 29], but this novel approach has only
recently begun to be formally tested, and there is
some uncertainty as to the optimal treatment
parameters. A consequence of this piecemeal
approach to long-term psoriasis treatment is that
it is unclear which of these methods is optimal, as
well as how long the efficacy and safety of such
treatments can be maintained. There is thus a
considerable need for clinical trials that are
designed to address relapse prevention.
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Long-term studies of topical agents for the
treatment of psoriasis that are currently available have certain limitations. These include, but
are not limited to, the nature of open-label
studies, relatively small patient populations, the
absence of a placebo arm, and the reliance on
self-reported patient measures as the final study
outcomes [30–32]. Moreover, the studies may be
characterized by inadequate safety assessments,
nonstandardized treatment dosing and administration, and lack of consensus on definitions
for treatment success and endpoints. A recent
review and position statement on the treatment
of psoriasis with vitamin D3 analogues, corticosteroids, and compound formulations
revealed that few, large, long-term, randomized,
blinded clinical trials have been conducted [30].
Among the few long-term studies that have
been done, one found that an ointment containing the vitamin D analogue calcipotriol
50 lg/g plus the corticosteroid betamethasone
dipropionate 0.5 mg/g (Cal/BD) was safe and
well tolerated when administered over a
52-week period [33]. Specifically, this study
found that Cal/BD ointment demonstrated a
favorable safety profile when used on its own or
alternating every 4 weeks with calcipotriol [33].
The incidence rate of AEs known to be associated with long-term corticosteroid use was low,
and adrenal function was assessed in a subset of
subjects [33]. An additional study demonstrated
that as-needed use of the fixed-combination
ointment for up to 52 weeks was not associated
with signs of adrenal suppression [34]. However,
rather than comparing a proactive vs a reactive
treatment strategy, the objectives of these
studies were to compare the safety [33] and
efficacy [35] of three different treatment regimens including (1) use of the two-compound
formulation by itself for 52 consecutive weeks,
(2) use of the two-compound product and calcipotriol alone in alternating 4-week periods for
up to 52 weeks, and (3) use of the two-compound product for 4 weeks followed by
48 weeks of calcipotriol ointment [35]. Assessments of efficacy were limited to investigator
global assessments of disease severity and
patient-reported treatment satisfaction [35].
In a long-term study examining scalp psoriasis, the safety and efficacy of a topical
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suspension of Cal/BD that was formulated for
use on the scalp were compared with calcipotriol alone during a reactive, 52-week paradigm in which patients stopped and restarted
treatment as needed [36]. When administered
reactively over a 52-week period, the two-compound scalp formulation did not increase the
rate of adverse drug reactions or AEs associated
with long-term use of topical corticosteroids,
and it further demonstrated increased efficacy
relative to reactive treatment with calcipotriol
alone [36]. However, proactive therapy was not
assessed, as this study used the conventional, asneeded reactive approach to treating scalp psoriasis, and the efficacy assessments were limited
to the Physician’s Global Assessment (PGA) of
disease severity and patient ratings of treatment
efficacy [36].
In the PSO-TOP study, patients applied a Cal/
BD topical suspension once daily for 8 weeks
followed by as-needed application for an additional 56 weeks [37]. The objective of the study
was to compare the clinical response related to
treatment optimization vs standard of care, not
to assess the safety and efficacy of topical therapy per se.
Finally, in a long-term open-label study,
subjects with moderate-to-severe plaque psoriasis were treated for 8 weeks with HP plus
tazarotene (HP/TAZ) lotion, with additional
treatment being administered in 4-week cycles
as needed for up to 1 year [38]. This study
reported on the long-term safety profile of HP/
TAZ, including assessments of AEs and tolerability. However, neither HPA axis function nor
efficacy was assessed using this reactive treatment regimen, and therefore no conclusions
can be drawn regarding these aspects of longterm treatment with HP/TAZ, the long-term
effects of HP/TAZ on adrenal suppression, or its
long-term efficacy.
As these long-term studies of topical treatments for psoriasis vulgaris indicate, there
remains a significant gap in the available data
for comparing the conventional reactive
approach vs proactive treatment strategies. This
will require robust randomized clinical trials
that incorporate longer treatment durations
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and appropriate sample sizes to achieve adequate power and improve clinical relevance.
Such trials will need to include well-defined and
extensive assessments of efficacy and safety,
because the available data from existing longterm studies are limited.
Calcipotriene Plus Betamethasone
Dipropionate (Cal/BD) Foam
as a Treatment Option for Psoriasis
Vulgaris
An alcohol-free aerosol foam formulation of the
fixed-combination Cal/BD that incorporates a
non-skin-drying emollient vehicle was recently
developed to improve treatment for patients
with psoriasis [23]. Compared with the Cal/BD
ointment [9, 23], the Cal/BD foam has
enhanced penetration and is considered to be
more cosmetically acceptable [9]. These features
could increase patient adherence and lead to
improved efficacy in a real-world setting [23].
Currently, Cal/BD foam is indicated for the
daily topical treatment of plaque psoriasis in
patients 12 years of age and older for up to
4 weeks [39].
The efficacy and safety of Cal/BD foam have
been evaluated in three 4-week clinical trials
involving approximately 1100 randomized
subjects [23, 40, 41]. In these short-term studies,
once-daily Cal/BD foam demonstrated greater
efficacy in treating psoriasis than did Cal/BD
ointment [40] and also greater efficacy than
foams containing the individual active ingredients [41]. Importantly, Cal/BD aerosolized foam
was well tolerated, with a favorable safety and
tolerability profile that was similar to that of
Cal/BD ointment and of the individual active
ingredients [23, 40, 41]. A 12-week study in
approximately 460 subjects revealed greater
disease improvements with Cal/BD foam than
with Cal/BD gel, and without detection of any
new safety signals [42]. Together, these studies
demonstrate the benefits of Cal/BD foam for the
topical treatment of mild, moderate, and severe
plaque psoriasis without compromise in safety
and tolerability.
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Trial Rationale
In the PSO-LONG trial, the use of Cal/BD foam
for maintenance therapy was investigated in a
novel, randomized, double-blind, long-term
(12-month) study. The long-term safety and
efficacy profile were rigorously assessed, and the
trial compared a proactive approach of a fixed,
twice-weekly maintenance regimen with use of
a conventional, reactive approach (i.e., the
vehicle control arm). Specifically, during the
long-term maintenance phase of the trial, subjects were randomly assigned to apply either
Cal/BD foam or vehicle twice weekly to a disease site that was previously cleared (or almost
cleared) during the preceding open-label phase.
In the event of relapse, which was defined as an
increase in the PGA to a score of at least ‘‘mild’’
(PGA = 2), subjects were directed to apply Cal/
BD foam to the active area once daily for
4 weeks, regardless of group assignment. This
phase 3 clinical trial was thus the first longterm comparison of the standard, as-needed
approach that is utilized in clinical practice with
a novel regimen that was designed to increase
patient adherence (and thus treatment outcomes) by including only twice-weekly proactive application of a single, dual-combination
product.
The objective of the PSO-LONG trial was to
assess the ability of Cal/BD foam to maintain
initial clinical efficacy for a longer period of
time than twice-weekly application of a vehicle.
In addition, this trial tested the hypothesis that
proactive treatment would prolong the time to
relapse and reduce relapse frequency while
maintaining safety, and that patients receiving
long-term maintenance therapy would demonstrate a superior response compared with vehicle patients in terms of the number of relapsefree days.
Although topical corticosteroids and vitamin D analogues are commonly used psoriasis
treatments, there are a number of safety considerations associated with their application,
particularly on large surface areas or over
extended periods of time [9]. Local cutaneous
side effects of topical corticosteroids include
skin atrophy, telangiectasia, striae distensae,
acne, folliculitis, and purpura [8]. The systemic
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side effects associated with topical corticosteroids
are relatively infrequent but can include
Cushing’s syndrome, osteonecrosis of the
femoral head, cataracts, glaucoma, and HPA
axis suppression [8]. Implementing more
sophisticated treatment regimens involving
corticosteroids, such as with proactive, fixed,
twice-weekly application, may allow for longer
treatment durations with reduced concern for
adrenal suppression [43]. Similarly, although
the side effect profile of vitamin D is generally
mild, systemic side effects such as hypercalcemia and parathyroid hormone suppression
may arise in extreme cases in which patients are
applying more than the recommended dosage
or have an underlying condition such as
impaired renal function or calcium metabolism
[8, 9]. Another possible concern with topical
corticosteroids is rebound, wherein the disease
recurs worse than the pretreatment baseline
after the treatment is discontinued [8].
Although rebound has been reported to occur
when topical corticosteroids are abruptly discontinued, this phenomenon is poorly characterized and requires further study [8]. Given
these important considerations, another goal of
the PSO-LONG trial was to evaluate the longterm safety of Cal/BD foam over extended
management of psoriasis in a comprehensive
manner. Accordingly, both local and systemic
safety assessments were included, such as calcium homeostasis and HPA axis changes related
to vitamin D analogue and corticosteroid treatment, respectively, as well as the incidence of
rebound.

METHODS
Study Design
PSO-LONG was a multicenter, prospective trial
that consisted of an initial open-label 4-week
treatment phase followed by a randomized,
double-blind, vehicle-controlled, maintenance
phase of up to 52 weeks in subjects with psoriasis vulgaris (Fig. 1). Regular study visits were
scheduled every 4 weeks from baseline during
the open-label phase through the end of the
maintenance phase, as detailed in Table 1.
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Screening/Washout Phase
Assessment of subject eligibility occurred at a
screening visit prior to a washout period. Eligible subjects included adults with psoriasis vulgaris on the trunk and/or limbs rated as at least
‘‘mild’’ according to the PGA, with body surface
area (BSA) involvement of 2–30%, and with a
modified Psoriasis Area and Severity Index (mPASI) score of at least 2 (see ‘‘Sample Selection’’
and Table 2). Prior to any trial-related procedure
(including washout), signed informed consent
was obtained from the subject. A washout period of up to 4 weeks was required for subjects
who were currently receiving, or who had
recently been treated with, anti-psoriatic treatments or other relevant medication not permitted as defined by the exclusion criteria (see
Tables 3 and 4). On completion of the washout
period, the subject’s ongoing eligibility for the
trial was confirmed at visit 1. If no washout was
needed, the subject could enter visit 1 directly.
Open-Label Treatment Phase
After the screening/washout phase, subjects
deemed eligible for the trial were enrolled in the
initial open-label phase, during which they
applied Cal/BD foam once daily on psoriatic
lesions on the trunk and/or limbs for 4 weeks.
All medication needed for 4 weeks was dispensed at visit 1, with the first application made
during the initial visit under the supervision
and instruction of the trial staff. At this time,
the subjects were given a treatment instruction
sheet describing the scenarios to be considered
depending on the different treatment phases,
and they also received verbal instruction about
how to apply the trial medication. Note that
there were different types of instructions for
open-label, maintenance, and relapse treatment
methods, and subjects were always reminded to
follow one of the particular instructions to
avoid confusion among the different treatment
phases. Subjects who achieved treatment success (PGA score of ‘‘clear’’ or ‘‘almost clear’’ with
at least a 2-grade improvement from baseline) at
week 4 (visit 2) were then randomized in a 1:1
ratio to a maintenance phase of up to 52 weeks
with Cal/BD foam or vehicle (maintenance
investigational product, IP) twice weekly.
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Subjects who did not achieve treatment success
were discontinued from the trial.
Maintenance Phase
During the randomized maintenance phase,
subjects received three cans of maintenance IP
every 4 weeks, which was sufficient for the visit
interval when used twice per week, as described
below. At each visit, the IP, including empty
containers dispensed at the previous visit, were
returned by the subject. The subjects applied
maintenance IP twice weekly 3 or 4 days apart
(according to subject preference, and on fixed
days throughout the trial, e.g., Thursday and
Sunday) on all areas on the trunk and limbs
where lesions had cleared or almost cleared
during the initial open-label phase or after
treatment of a relapse. To improve medication
adherence, electronic reminders were sent to
the subject every week on the selected application days. Subjects were assessed regularly at
clinical visits every 4 weeks. In addition, if, in
the opinion of the subject, a relapse (exacerbation of psoriasis) occurred between two regular
monthly visits, the subject was assessed by the
investigator at an unscheduled visit.
Following confirmation of a relapse, the subject was provided with rescue IP and asked to
apply it to any active area that was judged to be at
least ‘‘mild’’ according to the PGA, irrespective of
whether those areas were active at baseline or
were new lesions. The rescue IP was applied once
daily on the active areas for 4 weeks, with all
seven cans of rescue IP being dispensed to the
subjects upon initial confirmation of relapse to
ensure adequate supply throughout the 4-week
rescue period. If additional areas became active
during rescue treatment, those were also treated
once daily with rescue IP. During a relapse, areas
that were not active continued to receive twiceweekly maintenance treatment, as detailed
above. If a score of ‘‘clear’’ or ‘‘almost clear’’ was
regained after 4 weeks, the twice-weekly maintenance regimen was restarted on the now ‘‘clear’’
or ‘‘almost clear’’ area(s) according to the original
randomization scheme. If a score of ‘‘clear’’ or
‘‘almost clear’’ was not regained after the 4 weeks
of once-daily rescue treatment, then the subject
exited the trial.
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Fig. 1 Trial design. The boxed region and outset highlight the details of the 52-week maintenance phase. ACTH
adrenocorticotropic hormone, AE adverse event, Cal/BD calcipotriol 50 lg/g and betamethasone dipropionate 0.5 mg/g,
FU follow-up, UNS unscheduled visit, Relapse FU follow-up on relapse

Follow-up Phase
After the maintenance phase, there were three
types of follow-up visits (Table 1). Follow-up
visit 1 (FU1) was only relevant for subjects with
either an ongoing AE or abnormal laboratory
findings at the end of treatment. Follow-up
visit 2 (FU2) was only conducted for subjects
who underwent the adrenocorticotropic hormone (ACTH) challenge test and exhibited
signs of altered HPA axis function (serum cortisol concentrations B 18 lg/dL at 30 min after
ACTH challenge). If signs of adrenal

suppression were present at FU2, additional
ACTH challenge tests were performed until
adrenal suppression resolved. All subjects were
followed up for events of rebound for up to
8 weeks after the last application of maintenance IP. If a rebound was confirmed at followup visit 3 (FU3), the subject was followed up for
14 days or until resolution (whichever happened first), and this follow-up period may have
continued beyond the end of the clinical trial if
the rebound was considered to be a serious AE
(SAE).
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Table 1 continued

Xn

X

X

X

± 4 days

X

X

X

X

visit

p

UNS/relapse FU

X

X

X

after call

B 7 days

As needed

X

X

X

X

withdrawal

Early

FU1q,s

FU2r,s

Follow-up phase

X

X

X

FU3t
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X

X
X

X

V15

X

Xo

visit

p

UNS/relapse FU

X

X

X

withdrawal

Early

FU1q,s

FU2r,s

Follow-up phase

X

FU3t

Informed consent should be signed both by subject and (sub)investigator (medically qualiﬁed) before any trial-related procedures are carried out. For subjects requiring a washout period, informed consent

SV and visit 1 will be performed at the same time for subjects who do not need a washout period

A washout period of up to 4 weeks must be completed if the subject is currently being treated with, or has recently been treated with, anti-psoriatic treatments or other relevant medication, as deﬁned by the exclusion criteria

n

± 30 min after checking vital signs and collecting blood and urine samples

FU1 visit should only be performed if required, e.g., in case of a nonserious AE classiﬁed as possibly or probably related to the trial treatment or an SAE that is ongoing at the last on-treatment visit. In

UNS or relapse FU will be performed if a relapse of psoriasis occurs

Subjects are required to return Cal/BD foam dispensed during any UNS at the following relapse follow-up visit (relapse FU) or at the next regular 4-week visit

AM

FU2 visit is applicable for a subject having an ACTH challenge test and an end-of-treatment value of serum cortisol concentration B 18 lg/dL at 30 min after ACTH challenge; this visit would be

If both FU1 and FU2 are applicable (only applicable for subjects having HPA axis assessments), only FU2 (4 weeks after the last on-treatment visit) will be performed. All assessments applicable at FU1 will be done at FU2
Subjects will be followed up for up to 8 weeks after V15/early withdrawal for relapse/rebound evaluation. Subjects will call to make an appointment for FU3 if they experience worsening of their psoriasis. If

u

After the end-of-treatment visit (visit 15 or early withdrawal), only events of rebound are routinely collected

a subject has not had a rebound after 8 weeks, a ﬁnal contact takes place (at the investigator’s discretion; this could be as a telephone contact)

t

s

performed 4 weeks after the last on-treatment visit

r

circumstances when the (sub)investigator considers it appropriate, the FU1 visit may be performed as a telephone contact; this would be performed 2 weeks after the last on-treatment visit

q

p

o

At designated sites

Or earlier in case of early withdrawal for subjects who have completed at least 40 weeks of the trial from baseline

Only for subjects who gave consent for this procedure

At visit 8 (week 28) only

Applicable only to subjects for whom HPA axis assessments are performed. ACTH challenge test should be performed at 8:00

If albumin-corrected serum calcium is above the normal range, or if the calcium-to-creatinine ratio is above the normal range and judged as clinically signiﬁcant at this visit, sampling should be repeated at a follow-up visit

Treatment compliance will be recorded by the subject in an eDiary
In case of relapse, Cal/BD foam will be dispensed at any unscheduled visit during the maintenance phase

m

l

k

j

i

h

g

If albumin-corrected serum calcium is above the normal range, or if the calcium-to-creatinine ratio is above the normal range and judged as clinically signiﬁcant at this visit, sampling should be repeated at
the following visit (visit 3 or FU1)

f

Only applicable for women of child-bearing potential

AEs will be collected from the date of signing the informed consent form, i.e., during the washout period

e

d

should be completed prior to washout

c

b

a

ACTH adrenocorticotropic hormone, BSA body surface area, DLQI Dermatology Life Quality Index, EQ-5D-5L generic health questionnaire, FU follow-up, m-PASI modiﬁed Psoriasis Area and Severity
Index, SV screening visit, UNS unscheduled visit, V visit, WPAI:PSO Work Productivity and Activity Impairment: Psoriasis questionnaire

End-of-trial form

X

Drug compliance form

randomization

SVa

X

to

Visit 2

4 weeks
Visit 1b baseline
V14

V3

Maintenance phase

Open-label phase,

Screening

Return of IP

Table 1 continued
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Table 2 Criteria for inclusion and exclusion
Inclusion criteria
1. Signed and dated informed consent obtained prior to any trial-related activities (including washout period)
2. Age 18 years or above
3. A clinical diagnosis of psoriasis vulgaris for at least 6 months involving the trunk and/or limbs, amenable to treatment
with a maximum of 100 g of trial medication per week
4. Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) involving 2–30% BSA
5. PGA of at least ‘ mild’’ on trunk and limbs at visit 1
6. m-PASI score of at least 2 at visit 1
7. A target lesion/target location of at least 3 cm at its longest axis located on the body (i.e., not on the scalp, face, or
intertriginous areas), scoring at least 1 (mild) for each of redness, thickness, and scaliness, and scoring at least 4 in total
by the investigator’s assessment of severity of the target lesion/location
8. Women of childbearing potential must have a negative urine pregnancy test at visit 1
9. Women of childbearing potential must agree to use a highly effective method of birth control during the triala
10. Able to communicate with the investigator and understand and comply with the requirements of the trial
Additional inclusion criteria for subjects undergoing HPA axis test (assigned sites only)
11. Signed and dated informed consent obtained for having ACTH challenge tests performed
12. An extent of psoriasis vulgaris on trunk and/or limbs of disease severity (PGA) of at least ‘ moderate’’ affecting
between 10% and 30% BSA, excluding psoriatic lesions of the genitals and skin folds, at visit 1
13. At visit 1, a normal HPA axis function, including a serum cortisol concentration [ 5 lg/dL before ACTH challenge
and [ 18 lg/dL at 30 min after ACTH challenge
Exclusion criteria
1. Systemic treatment with biologic therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within
the following time periods prior to visit 1
Etanercept—within 4 weeks
Adalimumab, inﬂiximab—within 8 weeks
Ustekinumab—within 16 weeks
Secukinumab—within 12 weeks
Other products—within 4 weeks or 5 half-lives (whichever is longer)
2. Treatment with any of the following therapies within the following time periods prior to visit 1
Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris—within 4 weeks
Systemic treatment with apremilast—within 4 weeks
Treatment with any nonmarketed drug substance—within 4 weeks or 5 half-lives (whichever is longer)
Psoralen combined with ultraviolet A (PUVA) therapy—within 4 weeks
Ultraviolet B (UVB) therapy—within 2 weeks

4742

Adv Ther (2020) 37:4730–4753

Table 2 Criteria for inclusion and exclusion
Topical anti-psoriatic treatment on the trunk and/or limbs (except for emollients)—within 2 weeks
Topical treatment on the face, scalp, and skin folds with corticosteroids or vitamin D analogues—within 2 weeks
3. Severe and/or extensive scalp psoriasis, which, in the opinion of the investigator, requires treatment with potent or
super-potent corticosteroids, which will be prohibited during the trial
4. Preexisting overt atrophy or telangiectasia in treatment areas
5. Planned initiation of, or changes to, concomitant medication that could affect psoriasis vulgaris (e.g., beta blockers,
antimalarial drugs, lithium, ACE inhibitors) during the trial
6. Current diagnosis of guttate, erythrodermic, exfoliative, or pustular psoriasis
7. Subjects with any of the following conditions present on the treatment area: viral (e.g., herpes or varicella) lesions of
the skin, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or
tuberculosis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, ulcers, and wounds
8. Other inﬂammatory skin disorders (e.g., seborrheic dermatitis or contact dermatitis) on the treatment area that may
confound the evaluation of psoriasis
9. Planned excessive exposure of area(s) to be treated with trial medication to either natural or artiﬁcial sunlight
(including tanning booths, sun lamps, etc.) during the trial
10. Known or suspected disorders of calcium metabolism associated with hypercalcemia
11. Known or suspected hypersensitivity to component(s) of the investigational products
12. Current participation in any other interventional clinical trial
13. Previously screened in this trial
14. In the opinion of the investigator, the subject is unlikely to comply with the clinical trial protocol (e.g., due to
alcoholism, drug addiction, or psychotic state)
15. Women who are pregnant, wishing to become pregnant during the trial, or breastfeeding
16. Subjects in close afﬁliation with the trial personnel (e.g., immediate family member or subordinate) or a member of
the clinical trial personnel; subjects who are an employee of the sponsor or a contract research organization (CRO)
involved in the trial
17. Subjects who are institutionalized by court order or by local authority
Additional exclusion criteria for subjects undergoing HPA axis test (assigned sites only)
18. A history of allergic asthma, serious allergy, or serious allergic skin rash
19. Known or suspected hypersensitivity to component(s) of CortrosynTM (including cosyntropin/tetracosactide) (in the
USA) or SynacthenÒ (including tetracosactide) (in Europe)
20. The use of inhaled corticosteroids in the 4 weeks prior to visit 1 or during the trial
21. Systemic corticosteroid treatment in the 12 weeks prior to visit 1 or during the trial
22. Enzymatic inductors (e.g., barbiturates, phenytoin, rifampicin) within 4 weeks prior to visit 1 or during the trial
23. Systemic or topical cytochrome P450 inhibitors (e.g., ketoconazole, itraconazole, metronidazole) within 4 weeks prior
to visit 1 or during the trial. Topical ketoconazole within 2 weeks prior to visit 1
24. Hypoglycemic sulfonamides within 4 weeks prior to visit 1 or during the trial
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Table 2 continued
25. Antidepressant medications within 4 weeks prior to visit 1 or during the trial. Estrogen therapy (including
contraceptives), antidepressant medications, and any other medication known to affect cortisol levels or HPA axis
integrity within 4 weeks prior to baseline
26. Not following nocturnal sleep patterns
27. Any of the following conditions, whether known or suspected
Depression and endocrine disorders (e.g., Cushing’s disease, Addison’s disease, diabetes mellitus) known to affect cortisol
levels or HPA axis integrity
Cardiac disorders associated with abnormal QT intervals or rhythm disturbances including clinically signiﬁcant
bradycardia or tachycardia
Severe renal insufﬁciency
Severe haptic disorders
ACE angiotensin-converting enzyme, ACTH adrenocorticotropic hormone, BSA body surface area, HPA hypothalamic–pituitary–adrenal, m-PASI modiﬁed Psoriasis Area and Severity Index, PGA Physician’s Global Assessment
a
A highly effective method of birth control is deﬁned as one which results in a low failure rate (less than 1% per year) such
as implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence, or vasectomized partner.
The subjects must have used the contraceptive method continuously for at least 1 month prior to the pregnancy test, and
they must have continued using the contraceptive method for at least 1 week after the last application of trial medication. A
woman was deﬁned as not of child-bearing potential if she was postmenopausal (12 months with no menses without an
alternative medical cause) or surgically sterile (hysterectomy or bilateral ovariectomy)
Sample Selection
It was determined that between 178 and 190
subjects per group (380 total) were needed in
order to obtain a power of 90% for a 5% significance level. To achieve a total of 380 randomized subjects, an estimated 832 subjects
were screened. This screening and randomization process allowed for a sufficient number of
subjects after accounting for an anticipated
exponential decline and dropout rate of 30%
over 52 weeks. For the HPA axis test, up to 60
subjects (with BSA [ 10%) needed to be enrolled
to achieve approximately 30 randomized subjects at visit 2. Randomization of these subjects
was stratified by trial site, HPA axis testing, and
baseline disease severity (mild, moderate, severe). The maximum number of subjects enrolled
with ‘‘mild’’ disease according to the PGA was
capped at 20% to ensure similar distribution of
disease severity at baseline as in previous Cal/
BD foam short-term trials and, hence, a similar
trial population.

Reasons for withdrawal from the trial
included screening failure, lack of efficacy, AEs,
withdrawal by the subject, loss to follow-up,
death, or other relevant reasons. In addition, as
previously noted, subjects were withdrawn if
they did not achieve treatment success after the
initial 4-week open-label phase and/or if they
were unable to score ‘‘clear’’ or ‘‘almost clear’’
after a 4-week treatment for a relapse.
Measurements
Investigator and patient assessments were
recorded during each of the scheduled study
visits (Table 1), as well as during all unscheduled visits.
Clinical Assessments
All dermatologic assessments of the treatment
area were performed by a dermatologist, certified physician’s assistant, advanced registered
nurse practitioner, or general practitioner
experienced in treating psoriasis vulgaris. The
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Table 3 Prohibited medication, including nondrug therapies and procedures (for all subjects)
Prohibited medication, including nondrug
therapies and procedures

Location

Exclusion period restrictions

Systemic treatment with biologic therapies (marketed Not
Etanercept: within 4 weeks prior to visit 1
and nonmarketed), with a possible effect on
applicable Adalimumab, inﬂiximab: within 8 weeks prior to
psoriasis vulgaris
visit 1
Ustekinumab: within 16 weeks prior to visit 1
Secukinumab: within 12 weeks prior to visit 1
Other products: within 4 weeks or 5 half-lives prior
to visit 1 (whichever is longer) and any time during
the trial treatment phase
Systemic treatment with therapies other than
Not
Within 4 weeks prior to visit 1 and any time during
biologics, with a possible effect on psoriasis vulgaris
applicable
the trial treatment phase
(e.g., corticosteroids, retinoids, methotrexate,
cyclosporine, and other immunosuppressants)
Systemic treatment with apremilast

Not
Within 4 weeks prior to visit 1 and any time during
applicable
the trial treatment phase

Use of nonmarketed or other IPs

Body and
scalp

Within 4 weeks or 5 half-lives (whichever is longer)
prior to visit 1 and any time during the trial
treatment phase

PUVA

Body and
scalp

Within 4 weeks prior to visit 1 and any time during
the trial treatment phase

UVB therapy

Body and
scalp

Within 2 weeks prior to visit 1 and any time during
the trial treatment phase

Any topical treatment on the body or scalp, including Body and
corticosteroids (except for emollients, nonsteroidal
scalp
medicated shampoos, and low-potency
corticosteroids on sensitive areas)

Within 2 weeks prior to visit 1 and any time during
the trial treatment phase. On areas treated with IP,
emollients should not be used on days when IP is
being applied

Initiation of, or changes to, concomitant medication Not
Any time during the trial treatment phase
that could affect psoriasis vulgaris (e.g., beta
applicable
blockers, lithium, antimalaria drugs, ACE
inhibitors)
Vitamin D supplements [ 400 IU/day (note:
stable dose of vitamin D
supplements B 400 IU/day is permitted)

Not
Any time during the trial treatment phase
applicable
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Table 3 continued
Prohibited medication, including nondrug
therapies and procedures

Location

Excessive exposure of treated areas to either natural Body and
or artiﬁcial sunlight that may affect psoriasis
scalp
vulgaris (i.e., normal lifestyle outdoor activities are
permitted, but deliberate exposure to sunlight or
artiﬁcial ultraviolet light, as in tanning booths,
should be avoided)

Exclusion period restrictions
Any time during the trial treatment phase

ACE angiotensin-converting enzyme, PUVA psoralen combined with ultraviolet A, UVB ultraviolet B

Table 4 Prohibited medications, including nondrug therapies and procedures (for subjects included in the HPA axis test)
Prohibited medications, including nondrug therapies and
procedures

Location

Exclusion period restrictions

Systemic treatment with corticosteroids

Not
Within 12 weeks prior to visit 1 and any
applicable
time during the trial treatment phase

Inhaled corticosteroids

Not
Within 4 weeks prior to visit 1 and any
applicable
time during the trial treatment phase

Estrogen therapy (including contraceptives) or any other
medication known to affect cortisol levels or HPA axis
integrity

Not
Within 4 weeks prior to visit 1 and any
applicable
time during the trial treatment phase

Enzymatic inductors (e.g., barbiturates, phenytoin, rifampicin),
systemic or topical cytochrome P450 inhibitors (e.g.,
ketoconazole, itraconazole, metronidazole), hypoglycemic
sulfonamides, antidepressive medications

Body and
scalp

Within 4 weeks prior to visit 1 and any
time during the trial treatment phase

Topical ketoconazole

Body and
scalp

Within 2 weeks prior to visit 1 and any
time during the trial treatment phase

HPA hypothalamic–pituitary–adrenal

investigator made a global assessment of the
disease severity of psoriasis of the trunk and
limbs using the 5-point PGA scale, in which
0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. This assessment represented the average lesion severity and was based
on the condition of the disease at the time of
evaluation.
Investigators also assessed the extent and
severity of clinical signs of the subject’s psoriasis. These assessments excluded the head (face

and scalp), thus yielding an m-PASI score. The
extent of psoriatic involvement was recorded
for the arms, trunk, and legs using a scale that
ranges from 0 to 6, with 0 indicating no
involvement and 6 indicating 90–100%
involvement. The severity of the psoriatic
lesions in each of the three areas was recorded
for clinical signs of redness, thickness, and scaliness, with each clinical sign being scored on a
5-point scale, in which 0 = none, 1 = mild,
2 = moderate, 3 = severe, and 4 = very severe.
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These individual assessments were used to calculate a single measure of disease extent and
severity (i.e., the m-PASI score).
The involvement of psoriasis vulgaris on the
trunk and limbs was also measured by the
investigator’s assessment of BSA involvement.
This measurement was recorded as a percentage
of the total BSA, estimating that the surface of
the subject’s full, flat palm (with all five fingers)
equated to approximately 1% of the total BSA.
Finally, during the baseline visit, the investigator selected a target lesion of at least 3 cm
along its longest axis and recorded its location
in detail so that it could be easily identified and
assessed during all subsequent visits. The
severity of the target lesion continued to be
assessed throughout the study for clinical signs
of redness, thickness, and scaliness, per the
scales noted above.
Subject Assessments
Subjects made self-assessments of quality of life
(QOL) and health status/symptoms as specified
in the schedule of trial procedures (Table 1).
These self-assessments included the Dermatology Life Quality Index (DLQI), the psoriasisspecific version of the EuroQoL 5-dimensional
questionnaire (EQ-5D-5L-PSO), and the Work
Productivity and Activity Impairment: Psoriasis
(WPAI:PSO) scale, which were completed at the
trial site on an electronic tablet. Subjects completed the Psoriasis Symptom Severity Inventory (PSI), which is an eight-item measure that
assesses symptoms of itch, redness, scaling,
burning, cracking, stinging, flaking, and pain,
as scheduled (Table 1) and at home, on an
eDiary device that was provided to them for use
throughout the study. The subject’s global
assessment of disease severity was made on site
at all scheduled and unscheduled visits, and was
based on the condition of the disease at the
time of the evaluation and not in relation to the
condition at an earlier visit or time. To ensure
unbiased answers for questionnaires that were
completed on site, the patient-reported outcomes (PROs) were completed prior to any other
assessments.

Safety and Laboratory Assessments
Safety assessments included AEs, which were
collected by medically qualified personnel at all
visits throughout the study duration. Subjects
were particularly monitored for any cutaneous
side effects that can occur with topical corticosteroids and vitamin D analogues. The
assessment of local safety and tolerability consisted of signs assessed by the investigator and
symptoms reported by the subjects. The investigator assessed application-site reactions for
perilesional signs of erythema, edema, dryness,
and erosion. The subject assessed the symptom
of ‘‘application-site burning or pain.’’
Blood and urine samples were collected as
scheduled (Table 1) for planned laboratory
assessments. Blood samples were analyzed for
calcium, albumin, and 25-OH vitamin D, as well
as for biomarkers related to systemic inflammation, cardiovascular disease, and metabolic
syndrome in consenting participants. Additionally, blood samples were used for adrenal
function testing in a subset of subjects (approx.
30) whose psoriasis affected more than 10%
BSA. HPA axis function was considered as suppressed if serum cortisol was no greater than
18 lg/dL at 30 min after cosyntropin injections
administered during testing at weeks 4, 28, and
56 (trial end) or at early withdrawal. Laboratory
assessment of the urine samples reported calcium and creatinine levels and the calcium-tocreatinine ratio.
Planned Outcomes
Efficacy Endpoints
The primary efficacy endpoint was the time to
first relapse during the maintenance phase, in
which relapse was an exacerbation of psoriasis
defined by a PGA rating of at least mild. This
was calculated as the number of days from
randomization to the day at which the subject
had the first relapse confirmed. For subjects who
either did not experience a relapse or were
withdrawn from the trial, the number of days
was treated as a censored observation at the day
of the end-of-trial visit.
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Secondary efficacy endpoints included the
number of relapses during the maintenance
phase and the number of days each subject was
relapse-free, as indicated by a PGA score of
‘‘clear’’ or ‘‘almost clear.’’ Additional exploratory
efficacy endpoints included a summary of
m-PASI scores by visit, the number of relapsefree subjects at each visit, the time to when
PASI-75 was no longer fulfilled, the time to first
relapse according to m-PASI, and a summary of
the proportion of subjects who obtained ‘‘clear’’
or ‘‘almost clear’’ after treatment relapse separated by the number of relapses. The target
lesion scores, the affected BSA over time, the
number of active treatment days during the
maintenance phase, and the PROs regarding
QOL and health status also served as exploratory endpoints.
Safety Endpoints
Planned outcomes from safety assessments
included AEs associated with long-term corticosteroid use, the incidence of rebound, and
local safety and tolerability assessment scores.
Additional safety outcomes included analyses of
the effects of treatment on calcium metabolism
and HPA axis function.
Data Analysis
Trial Analysis Sets
All subjects enrolled in the trial were accounted
for in the clinical trial report. An open-label
safety analysis set was defined by including all
subjects exposed to treatment with the IP,
whether randomized or not. A maintenance
phase safety analysis set was defined by
excluding subjects from the full analysis set
who either received no treatment with IPs following randomization or provided no postrandomization safety evaluations, or both. All
randomized subjects were included in the full
analysis set and were analyzed for efficacy. A
per-protocol analysis set was defined by
excluding subjects from the full analysis set
who received no treatment with IPs after randomization, provided no efficacy data following
the start of maintenance treatment, were
known to have taken the wrong IPs throughout
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the maintenance phase, or did not fulfil the
disease-defining criteria.
Subject Disposition
The reasons for leaving the trial during the
open-label treatment phase were collected for
all included subjects by last visit attended. The
reasons for leaving the trial during the maintenance phase were collected for all randomized
subjects by treatment group and last visit
attended.
Baseline Demographics and Disease
Characteristics
Descriptive statistics of baseline demographics
and other characteristics were calculated for all
subjects included in the trial and for all randomized subjects by treatment group. A summary of age, sex, ethnicity, race, and baseline
m-PASI and PGA scores was provided according
to study center.
Efficacy Analyses
The primary endpoint was compared between
treatments and analyses performed both for the
full analysis set (primary) and for the per-protocol analysis set (supportive). The comparison
was done using a proportional hazards model
with treatment group, trial site, and disease
severity at baseline as factors. The estimate of
the hazard ratio of Cal/BD relative to vehicle,
together with the 95% confidence interval and
P value, was calculated. Additionally, the estimated survival curves with confidence intervals
were presented graphically for each treatment
group, with percentiles of the survival distribution tabulated by treatment group.
The secondary endpoints were analyzed for
the full analysis set, with the analysis for the
per-protocol analysis set being supportive, as
above. Adjustment for multiplicity was done
using the Holm–Bonferroni method. Specifically, for the number of relapses during the
maintenance phase, the data were analyzed in a
Poisson regression model with treatment group,
trial site, and disease severity at baseline as
factors, with subject as a random effect, and
with risk time as an offset. The estimated incidence rate ratio for active treatment group
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relative to vehicle group with 95% confidence
interval and P value was calculated. A sensitivity
analysis was also performed in which subjects
who at some point did not achieve ‘‘clear’’ or
‘‘almost clear’’ after treatment of a relapse were
excluded. For the number of days that each
subject was relapse-free, the data were analyzed
via analysis of variance (ANOVA) with treatment group, trial site, and disease severity at
baseline as factors. The estimated difference
between Cal/BD and vehicle groups was calculated with 95% confidence intervals and
P value. Two sensitivity analyses were performed with different handling of missing data.
In the first sensitivity analysis, the subject’s
observed part of the maintenance phase was
assumed to be representative for the unobserved
part of the maintenance phase when the subject
was withdrawn because of a non-drug-related
reason. The second sensitivity analysis was
based on a subject’s last observation carried
forward (LOCF) when the subject was withdrawn because of a non-drug-related reason. If a
subject withdrew from the trial for a drug-related reason, then in both sensitivity analyses,
the subject was not considered to be in a
relapse-free period from the time when the
subject left the trial.
All other exploratory analyses of efficacy and
PROs were analyzed for the full analysis set.
Both m-PASI scores and the number of relapsefree subjects at each visit were summarized by
visit and treatment group. PASI-75 was defined
as at least a 75% reduction in the m-PASI score
from baseline, and the time to when PASI-75
was no longer fulfilled during the maintenance
phase was compared between treatments using
a proportional hazards model with treatment
group, trial site, and disease severity at baseline
as factors. Relapse according to m-PASI level was
defined as the baseline m-PASI value minus 50%
of the reduction in m-PASI score obtained prior
to randomization for the maintenance phase.
The comparison between treatments of time to
first relapse according to m-PASI was made via a
proportional hazards model, as above, with the
estimated survival curves and confidence intervals calculated for each treatment group. For
each treatment group, the number of active
treatment days during the maintenance phase
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was calculated, and the proportion of subjects
who obtained ‘‘clear’’ or ‘‘almost clear’’ PGA
scores after treatment relapse was summarized
by the number of relapses. Target lesion scores
and the affected BSA were summarized over
time per treatment group.
Analysis of Safety
An analysis of AEs was performed for each phase
of the trial using that phase’s corresponding
safety population, as described above. AEs were
coded during the course of the trial according to
the Medical Dictionary for Regulatory Activities
and were categorized by preferred terms and
system organ class, as well as by treatment
group for those recorded during the maintenance phase. An overall summary of the number (percentage) of subjects with any treatmentemergent AE (TEAE), SAE, premature discontinuation from the trial due to an AE, treatment-related AE, and/or severe AE was planned.
The severity of each type of AE and the causal
relationship to the trial medication for each AE
was tabulated by treatment. For the maintenance phase, both the percentage of subjects
with AEs and the percentage of subjects with
related AEs were compared between treatment
groups via chi-square test or Fisher’s exact test
(if expected cell count was \ 5). AEs associated
with long-term topical corticosteroid use were
determined along with information about
demography and baseline characteristics. Additionally, the number of rebounds occurring
both within and after the first 2 months of
entering the maintenance phase were summarized by treatment group, and the number of
subjects with cases of rebound was calculated.
The local safety and tolerability signs
detailed above were summarized for both
treatment phases, with data being split by group
during the maintenance phase. For the subset of
subjects who underwent the ACTH challenge,
which was used for the HPA axis test, the
number of subjects with serum cortisol concentration B 18 lg/dL at 30 min after the ACTH
challenge was summarized over time by treatment group. The change in vital signs from
baseline to the end of the open-label phase and
from randomization to the end-of-trial visit was
also summarized. The change in each of the
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laboratory parameters from baseline to the end
of the open-label phase and from randomization to the end of the trial was summarized as
mean, standard deviation, median, minimum,
and maximum values, with values classified as
‘‘low,’’ ‘‘normal,’’ or ‘‘high’’ depending on whether they were below, within, or above the reference range.
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potential benefits for long-term patient care in
clinical practice. It was predicted that proactive
management would prolong the time to relapse
and reduce the frequency of relapses in patients
with psoriasis compared with vehicle, while
maintaining a favorable long-term safety
profile.
Study Strengths

STRENGTHS AND LIMITATIONS
The PSO-LONG trial adds data where there is a
dearth of evidence from robust, randomized
clinical trials that incorporate an extended
treatment period. The purpose of the trial was
to investigate whether Cal/BD foam can be used
by patients to provide safe and efficacious
proactive, long-term management of psoriasis.
Specifically, the trial investigated whether
twice-weekly (i.e., once per day on two nonconsecutive days) application of Cal/BD foam
was able to maintain the initial clinical efficacy
at PGA 0/1 for an extended period of time, as
compared with twice-weekly application of
vehicle. Because both treatment groups received
Cal/BD foam once daily for 4 weeks for rescue in
case of relapse during the maintenance phase,
the vehicle arm utilized a treat-as-needed
approach and thus reflected the normal clinical
use of the product. This allowed for the firstever comparison of a proactive vs a reactive
treatment strategy in a clinical trial evaluating
long-term treatment options for disease management in psoriasis.
Comparisons of Cal/BD foam and the two
other marketed Cal/BD formulations as an
ointment and gel suspension have shown that
the systemic safety profile and the short-term
AE profile of Cal/BD foam are similar to the
profiles of those formulations individually, with
no new safety concerns for Cal/BD foam beyond
those already described for the ointment and
gel suspension. On the basis of this, no specific
safety or tolerability concerns were anticipated
with the proposed long-term treatment.
In summary, the PSO-LONG study provided
evidence for the long-term safety and efficacy of
twice-weekly topical Cal/BD foam, the benefits
and limitations of proactive therapy, and

This was the first randomized, double-blind,
52-week clinical trial that evaluated long-term
safety and efficacy outcomes of a proactive
treatment regimen. This novel approach to the
long-term management of psoriasis was intended to keep patients in a relapse-free status
while maintaining a favorable safety profile.
Long-term use of products that contain
potent or super-potent topical corticosteroids
can lead to adverse cutaneous side effects, such
as skin atrophy and striae, as well as adrenocortical suppression and infection [8, 9]. Using
intermittent corticosteroid dosing in the maintenance treatment of psoriasis is a commonly
recommended approach, as it may control the
signs of psoriasis while reducing drug exposure
and thereby decreasing the risk of AEs [18].
Thus, the PSO-LONG study significantly augmented knowledge of the therapeutic benefit of
Cal/BD foam during the long-term treatment of
psoriasis as well as the safety profile of Cal/BD
foam, by assessing AEs often associated with
long-term corticosteroid treatment for psoriasis.
The present study also evaluated long-term
efficacy based on the hypothesis that subjects
who received Cal/BD foam twice weekly would
achieve superior responses over those receiving
vehicle, as indicated by a higher number of
relapse-free days during the maintenance phase.
The 12-month study duration allowed proper
analysis of relapse prevention over a period of
time during which subjects would typically be
expected to experience relapses. This particular
study also extended prior findings on the clinical efficacy of Cal/BD foam [23, 40–42].
Finally, this study provided a much-needed
comparison of a proactive, twice-weekly topical
psoriasis treatment against the reactive
approach that is commonly implemented in
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treatment strategies. This comparison provides
valuable evidence on the efficacy and safety of a
proactive treatment strategy with a dual-agent
topical therapy.
Study Limitations
Currently, there is no clear-cut, evidence-based
consensus on the use of a proactive maintenance regimen to keep patients with psoriasis
relapse-free. Clinicians may be hesitant to prescribe a proactive, long-term treatment regimen, and patients may be hesitant to comply
with such a strategy, because of safety concerns
associated with long-term topical corticosteroid
use. Further research may be needed to better
understand the barriers to use of the proactive
treatment method.
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